Rhenman & Partners Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.86M	Sell	379,250 -107,750	-22%	-$2.34M	1.09%	37
2025 Q4	$10.2M	Sell	487,000 -87,000	-15%	-$1.52M	0.96%	40
2025 Q3	$8.83M	Hold	574,000	–	–	0.98%	39
2025 Q2	$5.38M	Buy	574,000 +141,000	+33%	+$1.55M	0.68%	47
2025 Q1	$5.32M	Buy	433,000 +201,000	+87%	+$2.84M	0.61%	45
2024 Q4	$3.07M	Sell	232,000 -27,500	-11%	-$471K	0.32%	68
2024 Q3	$5M	Buy	259,500 +31,000	+14%	+$640K	0.41%	64
2024 Q2	$4.69M	Buy	228,500 +50,000	+28%	+$1.05M	0.45%	55
2024 Q1	$4.25M	Buy	+178,500	New	+$3.98M	0.4%	56

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return